Summary: Neurocrine Biosciences, Inc.

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Neurocrine Biosciences, Inc.

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses: Neurocrine Biosciences, Inc.

  • With an expected P/E ratio at 35.64 and 22.96 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings Chart: Neurocrine Biosciences, Inc.

Source: Surperformance

ESG chart: Neurocrine Biosciences, Inc.

Source: Refinitiv

Add to a list
Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
1.46TCr
13TCr
12TCr
- 2.78TCr
- 2.08TCr
1.74TCr
- 1.7TCr
1.54TCr
1.38TCr
- 1.23TCr
Average 3.83TCr
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG Refinitiv
C+

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Ratings Neurocrine Biosciences, Inc.